Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response

Wu, Yi-Ying; Sun, Te-Kai; Chen, Ming-Shan; Munir, Muhammad; Liu, Hung-Jen

doi:10.3389/fcimb.2023.1142172

Cited by 20 publications

(9 citation statements)

References 173 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3j ). VSVΔ51, like other oncolytic viruses, has been reported to induce immunogenic cell death (ICD) 16 . We thus asked if the increased viral replication induced by D2HG could induce stronger ICD.…”

Section: Resultsmentioning

confidence: 99%

IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma

Chen,

Liu,

et al. 2023

Nat Commun

View full text Add to dashboard Cite

IDH1 mutations frequently occur early in human glioma. While IDH1 mutation has been shown to promote gliomagenesis via DNA and histone methylation, little is known regarding its regulation in antiviral immunity. Here, we discover that IDH1 mutation inhibits virus-induced interferon (IFN) antiviral responses in glioma cells. Mechanistically, D2HG produced by mutant IDH1 enhances the binding of DNMT1 to IRF3/7 promoters such that IRF3/7 are downregulated, leading to impaired type I IFN response in glioma cells, which enhances the susceptibility of gliomas to viral infection. Furthermore, we identify DNMT1 as a potential biomarker predicting which IDH1mut gliomas are most likely to respond to oncolytic virus. Finally, both D2HG and ectopic mutant IDH1 can potentiate the replication and oncolytic efficacy of VSVΔ51 in female mouse models. These findings reveal a pivotal role for IDH1 mutation in regulating antiviral response and demonstrate that IDH1 mutation confers sensitivity to oncolytic virotherapy.

show abstract

Section: Resultsmentioning

confidence: 99%

IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma

Chen,

Liu,

et al. 2023

Nat Commun

View full text Add to dashboard Cite

show abstract

“…Moreover, the release of tumorassociated antigens (TAAs) or tumor-specific antigens (TSAs) from damaged tumor cells and their subsequent presentation by antigenpresenting cells (APCs) stimulate adaptive immune responses, which involve the activation of antigen-specific CD4+ and CD8+ T cells (84,85). Subsequently, these T cells that specifically target tumors can trigger immunogenic cell death in tumor cells, as confirmed in a preclinical investigation (86,87).…”

Section: Overview Of the Oncolytic Viruses And Cancer Immunotherapymentioning

confidence: 96%

Revolutionizing cancer treatment: the power of bi- and tri-specific T-cell engagers in oncolytic virotherapy

Zarezadeh Mehrabadi,

Tat,

Ghorbani Alvanegh

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Bi- or tri-specific T cell engagers (BiTE or TriTE) are recombinant bispecific proteins designed to stimulate T-cell immunity directly, bypassing antigen presentation by antigen-presenting cells (APCs). However, these molecules suffer from limitations such as short biological half-life and poor residence time in the tumor microenvironment (TME). Fortunately, these challenges can be overcome when combined with OVs. Various strategies have been developed, such as encoding secretory BiTEs within OV vectors, resulting in improved targeting and activation of T cells, secretion of key cytokines, and bystander killing of tumor cells. Additionally, oncolytic viruses armed with BiTEs have shown promising outcomes in enhancing major histocompatibility complex I antigen (MHC-I) presentation, T-cell proliferation, activation, and cytotoxicity against tumor cells. These combined approaches address tumor heterogeneity, drug delivery, and T-cell infiltration, offering a comprehensive and effective solution. This review article aims to provide a comprehensive overview of Bi- or TriTEs and OVs as promising therapeutic approaches in the field of cancer treatment. We summarize the cutting-edge advancements in oncolytic virotherapy immune-related genetic engineering, focusing on the innovative combination of BiTE or TriTE with OVs.

show abstract

“…Autophagy induction in the immunogenic cell death of cancer cells is triggered due to the recognition of pathogen-associated molecular pattern molecules (PAMPS), damage-associated molecular patterns (DAMPS), and other cellular stress signals released in response to NDV infection. NDV, in combination with autophagy modulators, enhances NDV anti-cancer activity [ 59 , 60 , 61 ]. Recombinant NDV-expressing rabies virus glycoprotein (rL-RVG) and LaSota induced stomach adenocarcinoma cell death via autophagy along with the activation of the ER stress response and apoptosis [ 62 ].…”

Section: Ndv-mediated Oncolysismentioning

confidence: 99%

The Viral Knock: Ameliorating Cancer Treatment with Oncolytic Newcastle Disease Virus

Pathak

Pal

Malik

2023

Life

View full text Add to dashboard Cite

The prospect of cancer treatment has drastically transformed over the last four decades. The side effects caused by the traditional methods of cancer treatment like surgery, chemotherapy, and radiotherapy through the years highlight the prospect for a novel, complementary, and alternative cancer therapy. Oncolytic virotherapy is an evolving treatment modality that utilizes oncolytic viruses (OVs) to selectively attack cancer cells by direct lysis and can also elicit a strong anti-cancer immune response. Newcastle disease virus (NDV) provides a very high safety profile compared to other oncolytic viruses. Extensive research worldwide concentrates on experimenting with and better understanding the underlying mechanisms by which oncolytic NDV can be effectively applied to intercept cancer. This review encapsulates the potential of NDV to be explored as an oncolytic agent and discusses current preclinical and clinical research scenarios involving various NDV strains.

show abstract

Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response

Cited by 20 publications

References 173 publications

IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma

IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma

Revolutionizing cancer treatment: the power of bi- and tri-specific T-cell engagers in oncolytic virotherapy

The Viral Knock: Ameliorating Cancer Treatment with Oncolytic Newcastle Disease Virus

Contact Info

Product

Resources

About